

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001819718  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer FULGENT GENETICS, INC.  
SEC File Number 001-37894  
Address of Issuer 4399 Santa Anita Ave  
El Monte  
CALIFORNIA  
91731  
Phone 626-350-0537  
Name of Person for Whose Account the Securities are To Be Sold Xie Jian

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1135	32370.2	30912392	12/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Common Stock 02/28/2022 Restricted stock vest	Fulgent Genetics, Inc.	<input type="checkbox"/>	32000	02/28/2022 Equity compensation for services rendered

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	09/03/2025	1128	24846.15
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	11/19/2025	10000	290982.76
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	11/24/2025	681	20752.08
Jian Xie C/O Fulgent Genetics, Inc. El Monte CA 91731	Common Stock	11/28/2025	1198	35424.27

## 144: Remarks and Signature

Remarks These shares were sold to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("sell-to-cover" transactions). The transaction, as well as other sales over the past three months (excluding the November 19, 2025 sale), do not represent discretionary trades by the Reporting Person. The November 19, 2025 sale was executed solely for year-end tax-planning purposes.

Date of Notice 12/01/2025

### ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Paul Kim as Attorney-in-Fact

**ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)**